All In Biotech

Drug Trial Radar · NCT07087054

Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen

A Randomized, Parallel Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Paltusotine in Adults With Carcinoid Syndrome Due to Well-Differentiated Neuroendocrine Tumors

Last checked: Nov 20, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 141 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

141

Planned (sponsor's estimate)

Start

Nov 19, 2025

Primary completion

Aug 2027

Study completion Jan 2030

Sponsor

Lead sponsor
Crinetics Pharmaceuticals Inc.Industry
Sponsor type
Industry
First posted
Jul 25, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 3, randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of paltusotine treatment vs placebo as well as the long-term safety of paltusotine in adults with carcinoid syndrome due to well-differentiated neuroendocrine tumors. The purpose of this study is to continue the evaluation of the safety, efficacy, and pharmacokinetics (PK) of paltusotine in participants with carcinoid syndrome.

Conditions

  • Carcinoid Syndrome
  • Carcinoid
  • Carcinoid Tumor
  • Carcinoid Tumor of Ileum
  • Carcinoid Tumor of Cecum
  • Carcinoid Tumor of Liver
  • Carcinoid Tumor of Pancreas
  • Carcinoid Syndrome Diarrhea
  • Carcinoid Intestine Tumor

Interventions

  • PaltusotineDrug

    Experimental Drug: Randomized

  • PlaceboDrug

    Matching Placebo Drug: Randomized

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Participants will record the number of flushing per day in a daily diary to assess the efficacy of paltusotine vs placebo in reducing flushing episodes.Time frame: Measured at Week 12

Locations

72 sites in 14 countries. Site status is shown where the registry gives one.

  • Banner MD Anderson Cancer Center

    Gilbert, Arizona

  • Hoag Memorial Hospital Presbyterian

    Newport Beach, California

  • Yale University - New Haven Hospital - Yale Cancer Center

    New Haven, Connecticut

  • University of Miami

    Miami, Florida

  • Moffitt Cancer Center

    Tampa, Florida

  • Winshop Cancer Institute - Emory University

    Atlanta, Georgia

  • University of Iowa Health Care

    Iowa City, Iowa

  • University of Kentucky Medical Center

    Lexington, Kentucky

  • Louisiana State University Health Sciences

    Metairie, Louisiana

  • Henry Ford Cancer - Detroit

    Detroit, Michigan

  • Mayo Clinic

    Rochester, Minnesota

  • Icahn School of Medicine at Mount Sinai

    New York, New York

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio

  • Hospital of the University of Pennsylvania

    Philadelphia, Pennsylvania

  • Huntsman Cancer Institute, University of Utah

    Salt Lake City, Utah

  • University of Virginia Comprehensive Cancer Center

    Charlottesville, Virginia

  • Medical College of Wisconcin

    Milwaukee, Wisconsin

  • Hospital de Gastroenterologia Dr. Carlos Bonorino Udaondo

    Buenos Aires, Argentina

  • Centro de Endocrinologia y Diabetes Dr. A. Gutman ICM - Investigaciones

    Buenos Aires, Argentina

  • Instituto Médico Especializado Alexander Fleming

    Buenos Aires, Argentina

  • Hospital de Gastroenterologia Dr. Carlos Bonorino Udaondo

    CABA, Argentina

  • Instituto Médico de la Fundación Estudios Clínicos

    Santa Fe, Argentina

  • Universitair Ziekenhuis (UZ) Leuven

    Leuven, Belgium

  • Fundacao PIO XII - Hospital de Amor Barretos

    Barretos, Brazil

  • Sociedade Literaria e Caritativa Santos Agostinho - Hospital Sao José

    Criciúma, Brazil

  • Nucleo de Pesquisa e Desenvolvimento de Medicamentos (MPDM)

    Fortaleza, Brazil

  • Associacao Hospitalar Moinhos de Vento

    Porto Alegre, Brazil

  • Instituto Nacional de Cancer (INCA)

    Rio de Janeiro, Brazil

  • AC Camargo Cancer Center

    São Paulo, Brazil, Brazil

  • CECIM-Centro de Estudios Cliicos e Investigaciones Medicas

    Santiago, Chile

  • Clinical Universidad Catolica del Maule, Ltda

    Maule, Chile, Chile

  • Centro de Oncologia de Precision

    Santiago, Chile, Chile

  • Hospital Universitario San Ignacio

    Bogotá, DC, Colombia

  • Instituto Nacional de Cancerologia

    Bogotá, DC, Colombia

  • CHRU Tours - Hopital Trousseau

    Chambray-lès-Tours, France

  • Hopital Beaujun - APHP

    Clichy, France

  • APHM- Hopital de la Timone

    Marseille, France

  • Centre Hospitalier Universitaire Nantes

    Nantes, France

  • Centre Antoine Lacassagne

    Nice, France

  • Groupe Hospitalier Diaconsses Croix Saint Simon

    Paris, France

Showing 40 of 72 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.